Table 1. Baseline characteristics of study participants.

	Nephroblastoma		Neuroblastoma		Controls
N	67		36		61
Male/female	39/28		15/21		33/28
Age at follow-up (yrs)	30.2 (18.8–50.8)		29.6 (20.4–46.2)		31.8 (18.0–61.8)
Age at diagnosis (yrs)	3.3 (0.0–12.7)		0.8 (0.0–11.7)		n.a.
Follow-up time * (yrs)	26.2 (6.4–48.9)		27.8 (15.0–44.4)		n.a.
BMI (SDS) **	−0.52 (−1.21–0.13)		−0.58 (−1.99–0.16)		0.08 (−0.51–0.68)
BMI at diagnosis (SDS) **	0.08 (−0.63–0.80)		0.31 (−0.61–0.74)		n.a.
Physical activity score **	8280 (6660–12000)		7130 (5843–9005)		8330 (6570–11370)
Non smoker	66%		50%		53%
Former smoker	12%		19%		16%
Smoker	22%		31%		31%
Low educational level	21%		22%		16%
Medium educational level	36%		33%		48%
High educational level	43%		45%		36%
(Partial) adrenalectomy (N)	33/67		13/36		n.a.
(Partial) nephrectomy (N)	67/67		7/36		n.a.
Radiotherapy abdomen (N)	35/67		7/36		n.a.
Radiotherapy thorax (N)	0/67		2/36		n.a.
Radiotherapy neck (N)	0/67		1/36		n.a.
Radiotherapy spine (N)	0/67		1/36		n.a.
Cumulative dose radiotherapy (gy)	20 (15–40)		20 (10–30)		n.a.
Chemotherapy (N)	59/67		31/36		n.a.
	N	TCD	N	TCD
Vincristin (mg/m2)	51	22.0 (6.0–93.0)	16	22.8 (5.0–65.0)	n.a.
Actinomycin D (mg/m2)	48	10.9 (0.1–24.8)	0	n.a.	n.a.
Anthracyclines (mg/m2)	18	250 (100–450)	12	210 (100–315)	n.a.
Cyclophosphamide (mg/m2)	2	3825 (250–7400)	29	7350 (3150–45990)	n.a.
Cisplatin (mg/m2)	0	0	6	450 (270–630)	n.a.
Teniposide (mg/m2)	0	0	6	500 (300–700)	n.a.
Dacarbazine (mg/m2)	2	14.7 (13.5–15.8)	0	0	n.a.
Iphosphamide (mg/m2)	2	33000 (30000–36000)	0	0	n.a.

Data expressed as median (range) unless specified otherwise.

^*Time after cessation of treatment.

^**Data expressed as median (interquartile range).

n.a. = not applicable, Gy = gray, TCD =  total cumulative dose.